These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 23638623)

  • 1. Glucocorticoid therapy as a significant risk factor for osteoporosis and fractures in an Italian postmenopausal population.
    Villa P; Moruzzi MC; Lassandro AP; Leoni F; Di Nardo F; De Waure C; Scambia G;
    Gynecol Endocrinol; 2013 Jul; 29(7):678-82. PubMed ID: 23638623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low bone mineral density, but not epidural steroid injection, is associated with fracture in postmenopausal women with low back pain.
    Yi Y; Hwang B; Son H; Cheong I
    Pain Physician; 2012; 15(6):441-9. PubMed ID: 23159959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucocorticoid induced risk of fractures.
    Maruotti N; Corrado A; Cantatore FP
    Panminerva Med; 2010 Dec; 52(4):339-43. PubMed ID: 21183894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary care use of FRAX: absolute fracture risk assessment in postmenopausal women and older men.
    Siris ES; Baim S; Nattiv A
    Postgrad Med; 2010 Jan; 122(1):82-90. PubMed ID: 20107292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Skeletal morbidity in inflammatory bowel disease.
    van Hogezand RA; Hamdy NA
    Scand J Gastroenterol Suppl; 2006; (243):59-64. PubMed ID: 16782623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteodensitometry in healthy postmenopausal women.
    Prescrire Int; 2008 Apr; 17(94):68-72. PubMed ID: 18536138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy.
    Van Staa TP; Laan RF; Barton IP; Cohen S; Reid DM; Cooper C
    Arthritis Rheum; 2003 Nov; 48(11):3224-9. PubMed ID: 14613287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucocorticoid-induced osteoporosis: a review on pathophysiology and treatment options.
    De Nijs RN
    Minerva Med; 2008 Feb; 99(1):23-43. PubMed ID: 18299694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of teriparatide in postmenopausal women with osteoporosis and glucocorticoid use: 3-year results from the EFOS study.
    Karras D; Stoykov I; Lems WF; Langdahl BL; Ljunggren Ö; Barrett A; Walsh JB; Fahrleitner-Pammer A; Rajzbaum G; Jakob F; Marin F
    J Rheumatol; 2012 Mar; 39(3):600-9. PubMed ID: 22247365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of osteopenic women at high risk of fracture: the OFELY study.
    Sornay-Rendu E; Munoz F; Garnero P; Duboeuf F; Delmas PD
    J Bone Miner Res; 2005 Oct; 20(10):1813-9. PubMed ID: 16160738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategies for treatment to prevent fragility fractures in postmenopausal women.
    Geusens P
    Best Pract Res Clin Rheumatol; 2009 Dec; 23(6):727-40. PubMed ID: 19945685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrogen receptor beta (ESR2) polymorphisms in interaction with estrogen receptor alpha (ESR1) and insulin-like growth factor I (IGF1) variants influence the risk of fracture in postmenopausal women.
    Rivadeneira F; van Meurs JB; Kant J; Zillikens MC; Stolk L; Beck TJ; Arp P; Schuit SC; Hofman A; Houwing-Duistermaat JJ; van Duijn CM; van Leeuwen JP; Pols HA; Uitterlinden AG
    J Bone Miner Res; 2006 Sep; 21(9):1443-56. PubMed ID: 16939403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relationship between back pain and future vertebral fracture in postmenopausal women.
    Kuroda T; Shiraki M; Tanaka S; Shiraki Y; Narusawa K; Nakamura T
    Spine (Phila Pa 1976); 2009 Aug; 34(18):1984-9. PubMed ID: 19680106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency of FRAX risk factors in osteopenic postmenopausal women with and without history of fragility fracture.
    Baró F; Cano A; Sánchez Borrego R; Ferrer J; González Rodríguez SP; Neyro JL; Rodriguez Bueno E; Sancho C; Inaraja V; Fernández C; Corral C;
    Menopause; 2012 Nov; 19(11):1193-9. PubMed ID: 22948137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vertebral fracture and bone mineral density in women receiving high dose glucocorticoids for treatment of autoimmune diseases.
    Kumagai S; Kawano S; Atsumi T; Inokuma S; Okada Y; Kanai Y; Kaburaki J; Kameda H; Suwa A; Hagiyama H; Hirohata S; Makino H; Hashimoto H
    J Rheumatol; 2005 May; 32(5):863-9. PubMed ID: 15868623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucocorticoid-induced osteoporosis: an update.
    Mazziotti G; Angeli A; Bilezikian JP; Canalis E; Giustina A
    Trends Endocrinol Metab; 2006; 17(4):144-9. PubMed ID: 16678739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An update on glucocorticoid-induced osteoporosis.
    Woolf AD
    Curr Opin Rheumatol; 2007 Jul; 19(4):370-5. PubMed ID: 17551369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Secondary osteoporosis or secondary contributors to bone loss in fracture. Therapeutic strategy for glucocorticoid-induced osteoporosis].
    Hayakawa N; Suzuki A
    Clin Calcium; 2013 Sep; 23(9):1337-44. PubMed ID: 23999371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The disconnect between better quality of glucocorticoid-induced osteoporosis preventive care and better outcomes: a population-based cohort study.
    Majumdar SR; Lix LM; Morin SN; Yogendran M; Metge CJ; Leslie WD
    J Rheumatol; 2013 Oct; 40(10):1736-41. PubMed ID: 23818715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of postmenopausal osteoporosis in Italy and validation of decision rules for referring women for bone densitometry.
    D'Amelio P; Spertino E; Martino F; Isaia GC
    Calcif Tissue Int; 2013 May; 92(5):437-43. PubMed ID: 23334353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.